Mechanisms of renal protection against disseminated candidiasis

抵抗播散性念珠菌病的肾脏保护机制

基本信息

项目摘要

ABSTRACT Candida albicans is a commensal fungus that causes severe disseminated candidiasis (DC) via indwelling catheters, abdominal surgery or other clinical interventions. DC is the 3rd most common hospital-acquired infection, with fatality rates up to 40-60%, and there are no vaccines to this or any other fungi. Following bloodstream infection, Candida hyphae invades and damages kidney tissue, and mortality is due to renal insufficiency in 30-50% of the patients. Treatment is hampered by challenges in early diagnosis, drug resistance, and a poor mechanistic understanding of protective immunity. Hence, there is a serious unmet clinical need to develop better therapeutic strategies to combat kidney damage in DC. The proinflammatory cytokine Interleukin- 17 (IL-17) has emerged as a key mediator of antifungal immunity. We discovered an unexpected renal tissue protective role for IL-17 in DC. In the absence of IL-17 signaling, renal tubular epithelial cells (RTEC) undergo increased apoptosis in DC. We also showed that IL-17 activates Kallikrein-Kinin System (KKS) which in turn upregulates kidney protective bradykinin in the infected kidney. However, the mechanisms by which IL-17- bradykinin-axis protects RTEC from apoptotic cell death in DC is unknown. Our preliminary data show that mice lacking IL-17 signaling exhibit reduced renal expression of multiple nicotinamide adenine dinucleotide (NADH): ubiquinone oxidoreductase genes in DC, which are critical for mitochondrial function. The lack of Ndufs activity is associated with mitochondrial dysfunction, a key driver of apoptosis. IL-17 and bradykinin signaling in RTEC converge to induce tissue type plasminogen activator (tPA), a serine protease known to prevent the activation of pro-apoptotic events downstream of mitochondrial dysfunction via binding to cell surface receptor CD91. The overall goal of this proposal is to determine the mechanisms of IL-17-bradykinin-axis mediated kidney tissue protection in DC and ultimately to utilize this knowledge for the treatment of kidney damage. To that end, we will use RTEC specific deletion of CD91 to define the role for tPA/CD91 pathway in protecting RTEC from mitochondrial dysfunction and apoptosis (Aim 1A). We will interrogate the cellular signaling events downstream of tPA/CD91 pathway in protection against apoptosis following fungal infection (Aim 1B). Knowledge gained from these studies will be used in pre-clinical studies to evaluate the therapeutic efficacy of treating mice with tPA in protection against the kidney damage in DC (Aim 2). Our long-term goal is to reduce the morbidity and mortality associated with this devastating hospital-acquired infection.
抽象的 白色念珠菌是一种共生真菌,可通过留置引起严重的播散性念珠菌病 (DC) 导管、腹部手术或其他临床干预措施。 DC 是第三大最常见的医院获得性疾病 感染,死亡率高达 40-60%,并且没有针对这种真菌或任何其他真菌的疫苗。下列的 血流感染,念珠菌菌丝侵入并损害肾组织,因肾病而死亡 30-50%的患者存在功能不足。早期诊断、耐药性等方面的挑战阻碍了治疗 对保护性免疫的机制了解不足。因此,存在严重未满足的临床需求 制定更好的治疗策略来对抗 DC 的肾脏损伤。促炎细胞因子白细胞介素 17 (IL-17) 已成为抗真菌免疫的关键介质。我们发现了意想不到的肾组织 IL-17 在 DC 中的保护作用。在缺乏 IL-17 信号传导的情况下,肾小管上皮细胞 (RTEC) 会经历 DC细胞凋亡增加。我们还表明 IL-17 激活激肽释放酶-激肽系统 (KKS),进而 upregulates kidney protective bradykinin in the infected kidney.然而,IL-17-的机制 缓激肽轴保护 RT​​EC 免受 DC 细胞凋亡的影响尚不清楚。我们的初步数据表明,小鼠 缺乏 IL-17 信号传导会导致多种烟酰胺腺嘌呤二核苷酸 (NADH) 的肾表达降低: DC 中的泛醌氧化还原酶基因对线粒体功能至关重要。缺乏 Ndufs 活性 与线粒体功能障碍有关,线粒体功能障碍是细胞凋亡的关键驱动因素。 RTEC 中的 IL-17 和缓激肽信号传导 汇聚诱导组织型纤溶酶原激活剂 (tPA),这是一种已知可防止激活的丝氨酸蛋白酶 通过与细胞表面受体 CD91 结合,抑制线粒体功能障碍下游的促凋亡事件。这 该提案的总体目标是确定 IL-17 缓激肽轴介导肾组织的机制 保护 DC 并最终利用这些知识来治疗肾脏损伤。 To that end, we will 使用 RTEC 特异性删除 CD91 来定义 tPA/CD91 通路在保护 RT​​EC 免受损害方面的作用 线粒体功能障碍和细胞凋亡(目标 1A)。我们将询问下游的细胞信号事件 tPA/CD91 通路在真菌感染后防止细胞凋亡的作用(目标 1B)。获得的知识来自 这些研究将用于临床前研究,以评估用 tPA 治疗小鼠的治疗效果 防止 DC 中的肾脏损伤(目标 2)。我们的长期目标是降低发病率和死亡率 与这种毁灭性的医院获得性感染有关。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Local antifungal immunity in the kidney in disseminated candidiasis.
  • DOI:
    10.1016/j.mib.2021.04.005
  • 发表时间:
    2021-08
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Jawale CV;Biswas PS
  • 通讯作者:
    Biswas PS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Partha Sarathi Biswas其他文献

Correction: Genomic prediction and QTL analysis for grain Zn content and yield in Aus-derived rice populations
  • DOI:
    10.1007/s13562-025-00983-8
  • 发表时间:
    2025-04-28
  • 期刊:
  • 影响因子:
    1.500
  • 作者:
    Tapas Kumer Hore;C. H. Balachiranjeevi;Mary Ann Inabangan-Asilo;C. A. Deepak;Alvin D. Palanog;Jose E. Hernandez;Glenn B. Gregorio;Teresita U. Dalisay;Maria Genaleen Q. Diaz;Roberto Fritsche Neto;Md. Abdul Kader;Partha Sarathi Biswas;B. P. Mallikarjuna Swamy
  • 通讯作者:
    B. P. Mallikarjuna Swamy

Partha Sarathi Biswas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Partha Sarathi Biswas', 18)}}的其他基金

RNA binding proteins in end-organ autoimmune pathology
终末器官自身免疫病理学中的 RNA 结合蛋白
  • 批准号:
    10569112
  • 财政年份:
    2022
  • 资助金额:
    $ 19.65万
  • 项目类别:
RNA binding proteins in end-organ autoimmune pathology
终末器官自身免疫病理学中的 RNA 结合蛋白
  • 批准号:
    10450945
  • 财政年份:
    2022
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of renal protection against disseminated candidiasis
抵抗播散性念珠菌病的肾脏保护机制
  • 批准号:
    10190010
  • 财政年份:
    2021
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of neutrophil dysfunction in antifungal immunity
中性粒细胞功能障碍在抗真菌免疫中的机制
  • 批准号:
    10454893
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of neutrophil dysfunction in antifungal immunity
中性粒细胞功能障碍在抗真菌免疫中的机制
  • 批准号:
    9815169
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of neutrophil dysfunction in antifungal immunity
中性粒细胞功能障碍在抗真菌免疫中的机制
  • 批准号:
    10223106
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of neutrophil dysfunction in antifungal immunity
中性粒细胞功能障碍在抗真菌免疫中的机制
  • 批准号:
    10673766
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
Regulation of IL-17 signaling by RNA binding proteins in kidney diseases
RNA 结合蛋白在肾脏疾病中调节 IL-17 信号传导
  • 批准号:
    9762270
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of IL-17 Mediated Host Defense in the Kidney
IL-17 介导的肾脏宿主防御机制
  • 批准号:
    9023669
  • 财政年份:
    2015
  • 资助金额:
    $ 19.65万
  • 项目类别:
Mechanisms of IL-17 Mediated Host Defense in the Kidney
IL-17 介导的肾脏宿主防御机制
  • 批准号:
    9144776
  • 财政年份:
    2015
  • 资助金额:
    $ 19.65万
  • 项目类别:

相似海外基金

AcT-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (AcT) trial.
AcT-Cog:阿替普酶与替奈普酶 (AcT) 试验相比的在线认知评估。
  • 批准号:
    444794
  • 财政年份:
    2021
  • 资助金额:
    $ 19.65万
  • 项目类别:
    Operating Grants
INTERRAcT: Thrombus characteristics for predicting Reperfusion with Alteplase compared to Tenecteplase
INTERRAcT:与替奈普酶相比,阿替普酶预测再灌注的血栓特征
  • 批准号:
    433102
  • 财政年份:
    2020
  • 资助金额:
    $ 19.65万
  • 项目类别:
    Operating Grants
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial
阿替普酶与替奈普酶治疗急性缺血性中风患者的比较:QuICR
  • 批准号:
    401715
  • 财政年份:
    2019
  • 资助金额:
    $ 19.65万
  • 项目类别:
    Operating Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : 1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 19.65万
  • 项目类别:
    Project Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : GNT1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 19.65万
  • 项目类别:
    Project Grants
Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study
低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风:一项基于影像学的安全性和有效性研究
  • 批准号:
    nhmrc : 510722
  • 财政年份:
    2008
  • 资助金额:
    $ 19.65万
  • 项目类别:
    NHMRC Project Grants
Treament of Deep Vein Thrombosis with Alteplase
阿替普酶治疗深静脉血栓
  • 批准号:
    7004919
  • 财政年份:
  • 资助金额:
    $ 19.65万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8565339
  • 财政年份:
  • 资助金额:
    $ 19.65万
  • 项目类别:
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    7593114
  • 财政年份:
  • 资助金额:
    $ 19.65万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8952839
  • 财政年份:
  • 资助金额:
    $ 19.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了